SECURITIES AND EXCHANGE COMMISSION
  
  Washington, DC  20549
  
  FORM 8-K
  
  CURRENT REPORT    
  
  Pursuant to Section 13 or 15(d) of the
  Securities Exchange Act of 1934
  
  October 4, 1994
  
  Mallinckrodt Group Inc.
  (Exact name of registrant as specified in its charter)
  
  New York                  
  (State or other jurisdiction             
   of incorporation)             
  
  1-483
  (Commission File Number)
  
  36-1263901
  (IRS Employer Identification No.)
  
  7733 Forsyth Boulevard, St. Louis, MO                   
  (Address of principal executive offices)                     
  
  63105-1820
  (Zip Code)
  
  Registrant's telephone number including area code
  (314) 854-5200
    <PAGE>
Item 5.  Other Events
  A press release was issued October 4, 1994.  The text of that
  release is as follows:
  
  MALLINCKRODT GROUP CEO REAFFIRMS FISCAL 1995 GROWTH OUTLOOK
  
  New York, N.Y., October 4, 1994  --  Talking with Wall Street
  analysts here today, Mallinckrodt Group Inc. (NYSE:MKG)
  President and Chief Executive Officer C. Ray Holman said that
  he expects a modest increase in ongoing earnings in the first
  quarter ended September 30, 1994, compared to the 43 cents
  earned last year before unusual items.  Many of the factors
  impacting first quarter results are also expected to continue
  in the first half.  Earnings for all of fiscal 1995 are
  expected to be more in line with long-range earnings growth
  expectations, about 15 percent year over-year, excluding one-
  time items in 1994.
  
     "We are confident in our expectations for health earnings
  gains in 1995 and beyond.  As stated in August, however, the
  year is off to a slow start, particularly in the animal health
  business," Holman said.  "We expect Mallinckrodt Veterinary to
  be down year-to-year in the first quarter due to weak food
  animal markets, higher raw material costs and lower pricing for
  feed ingredients, revised buying patterns by certain North
  American customers and adverse weather conditions in Australia
  and New Zealand.
  
     "Mallinckrodt Chemical earnings for the first quarter will
  also be down, due to an expected decline in acetaminophen
  sales, attributable to customer purchase adjustments, and to a
  temporary increase in manufacturing costs in the St. Louis
  production facility.  The decline will be more than offset by a
  very strong quarter for the Tastemaker join venture," he added.
  
     Mallinckrodt Medical sales and earnings for the first
  quarter are expected to be higher, but earnings will be
  affected by upfront costs associated with changes in the U.S.
  sales organization and new product launches.
  
     Commenting on expectations for each business for the full
  year, Holman said that he expects savings from the Mallinckrodt
  Veterinary restructuring program and new product introductions
  to contribute to a solid earnings gain.  He said that he is
  confident the industry knowledge and mangement expertise
  brought to the company by its new president will have a
  positive impact on performance.  On Monday, Mallinckrodt
  announced that Paul D. Cottone, former vice president of U.S.
  operations for the Merck AgVet Division, had been named
  president of Mallinckrodt Veterinary.
  
     "We expect to see double digit earnings gains from
  Mallinckrodt Medical in 1995," Holman said.  "This growth
  should be driven by new products and continuing sales growth in
  other products, along with the restructuring program which
  currently is being implemented.  Mallinckrodt Chemical will
  also experience double digit earnings gains, benefiting from
  expanded international acetaminophen sales, and continuing
  improvements in its catalyst business, boosted by last year's
  acquisition of Catalyst Resources, Inc.  Our Tastemaker joint
  venture is also expected to show continued strength in 1995."
  
     Mallinckrodt Group Inc., a St. Louis, Missouri-based
  Fortune 250 company, had fiscal 1994 net sales of $1.94
  billion.  Its three international technology-based businesses -
  - Mallinckrodt Chemical and Mallinckrodt Medical, also
  headquartered in the St. Louis area, and Mallinckrodt
  Veterinary, headquartered in Mundelein, Illinois -- provide
  specialty chemicals and human and animal health products. 
  Mallinckrodt has 10,200 employees worldwide.
  
  Pursuant to the requirements of the Securities Exchange Act of
  1934, the registrant has duly caused this report to be signed
  on its behalf by the undersigned thereunto duly authorized.
  
  
  Mallinckrodt Group Inc.
  
  
  
  
  ROGER A. KELLER
  Vice President, Secretary and General Counsel
  
  DATE:   October 28, 1994
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 4714}]
{"company-data": {"conformed-name": "MALLINCKRODT GROUP INC", "cik": "0000051396", "assigned-sic": "2834", "irs-number": "361263901", "state-of-incorporation": "NY", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-00483", "film-number": "94555644"}, "business-address": {"street1": "7733 FORSYTH BOULEVARD", "city": "ST LOUIS", "state": "MO", "zip": "63105", "phone": "314-854-5299"}, "mail-address": {"street1": "7733 FORSYTH BLVD", "city": "ST. LOUIS", "state": "MO", "zip": "63105-1820"}, "former-company": [{"former-conformed-name": "IMCERA GROUP INC", "date-changed": "19920703"}, {"former-conformed-name": "INTERNATIONAL MINERALS & CHEMICAL CORP", "date-changed": "19900614"}]}
SECURITIES AND EXCHANGE COMMISSION
  
  Washington, DC  20549
  
  FORM 8-K
  
  CURRENT REPORT    
  
  Pursuant to Section 13 or 15(d) of the
  Securities Exchange Act of 1934
  
  October 4, 1994
  
  Mallinckrodt Group Inc.
  (Exact name of registrant as specified in its charter)
  
  New York                  
  (State or other jurisdiction             
   of incorporation)             
  
  1-483
  (Commission File Number)
  
  36-1263901
  (IRS Employer Identification No.)
  
  7733 Forsyth Boulevard, St. Louis, MO                   
  (Address of principal executive offices)                     
  
  63105-1820
  (Zip Code)
  
  Registrant's telephone number including area code
  (314) 854-5200
Item 5.  Other Events
  A press release was issued October 4, 1994.  The text of that
  release is as follows:
  
  MALLINCKRODT GROUP CEO REAFFIRMS FISCAL 1995 GROWTH OUTLOOK
  
  New York, N.Y., October 4, 1994  --  Talking with Wall Street
  analysts here today, Mallinckrodt Group Inc. (NYSE:MKG)
  President and Chief Executive Officer C. Ray Holman said that
  he expects a modest increase in ongoing earnings in the first
  quarter ended September 30, 1994, compared to the 43 cents
  earned last year before unusual items.  Many of the factors
  impacting first quarter results are also expected to continue
  in the first half.  Earnings for all of fiscal 1995 are
  expected to be more in line with long-range earnings growth
  expectations, about 15 percent year over-year, excluding one-
  time items in 1994.
  
     "We are confident in our expectations for health earnings
  gains in 1995 and beyond.  As stated in August, however, the
  year is off to a slow start, particularly in the animal health
  business," Holman said.  "We expect Mallinckrodt Veterinary to
  be down year-to-year in the first quarter due to weak food
  animal markets, higher raw material costs and lower pricing for
  feed ingredients, revised buying patterns by certain North
  American customers and adverse weather conditions in Australia
  and New Zealand.
  
     "Mallinckrodt Chemical earnings for the first quarter will
  also be down, due to an expected decline in acetaminophen
  sales, attributable to customer purchase adjustments, and to a
  temporary increase in manufacturing costs in the St. Louis
  production facility.  The decline will be more than offset by a
  very strong quarter for the Tastemaker join venture," he added.
  
     Mallinckrodt Medical sales and earnings for the first
  quarter are expected to be higher, but earnings will be
  affected by upfront costs associated with changes in the U.S.
  sales organization and new product launches.
  
     Commenting on expectations for each business for the full
  year, Holman said that he expects savings from the Mallinckrodt
  Veterinary restructuring program and new product introductions
  to contribute to a solid earnings gain.  He said that he is
  confident the industry knowledge and mangement expertise
  brought to the company by its new president will have a
  positive impact on performance.  On Monday, Mallinckrodt
  announced that Paul D. Cottone, former vice president of U.S.
  operations for the Merck AgVet Division, had been named
  president of Mallinckrodt Veterinary.
  
     "We expect to see double digit earnings gains from
  Mallinckrodt Medical in 1995," Holman said.  "This growth
  should be driven by new products and continuing sales growth in
  other products, along with the restructuring program which
  currently is being implemented.  Mallinckrodt Chemical will
  also experience double digit earnings gains, benefiting from
  expanded international acetaminophen sales, and continuing
  improvements in its catalyst business, boosted by last year's
  acquisition of Catalyst Resources, Inc.  Our Tastemaker joint
  venture is also expected to show continued strength in 1995."
  
     Mallinckrodt Group Inc., a St. Louis, Missouri-based
  Fortune 250 company, had fiscal 1994 net sales of $1.94
  billion.  Its three international technology-based businesses -
  - Mallinckrodt Chemical and Mallinckrodt Medical, also
  headquartered in the St. Louis area, and Mallinckrodt
  Veterinary, headquartered in Mundelein, Illinois -- provide
  specialty chemicals and human and animal health products. 
  Mallinckrodt has 10,200 employees worldwide.
  
  Pursuant to the requirements of the Securities Exchange Act of
  1934, the registrant has duly caused this report to be signed
  on its behalf by the undersigned thereunto duly authorized.
  
  
  Mallinckrodt Group Inc.
  
  
  
  
  ROGER A. KELLER
  Vice President, Secretary and General Counsel
  
  DATE:   October 28, 1994